Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF2
AssigneeBrandeis University
InventorsGreg Petsko, Dagmar Ringe, Shulin Ju
Life of this patent
Estimating the term…
Abstract
Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.
Claims16
A method of reducing TAR-DNA-binding protein 43 (TDP-43)-mediated neuronal cytotoxicity in a human subject suffering from amyotrophic lateral sclerosis (ALS), wherein the human subject does not have a mutation in a SOD1 gene, the method comprising:
- administering to the human subject a composition comprising a UPF2 polypeptide or a nucleic acid encoding the UPF2 polypeptide or a vector comprising the nucleic acid encoding the UPF2 polypeptide, thereby reducing the TDP-43-mediated neuronal cytotoxicity in the human subject, wherein the UPF2 polypeptide comprises the amino acid sequence of SEQ ID NO:4.
A method of reducing fused in sarcoma/translocated in sarcoma (FUS/TLS)- or TDP-43-mediated neuronal cytotoxicity in a neuronal or glial cell in need thereof, wherein the neuronal or glial cell does not have a SOD1 mutation, the method comprising:
- providing to the neuronal or glial cell a composition comprising a UPF2 polypeptide or a nucleic acid encoding the UPF2 polypeptide or a vector comprising the nucleic acid encoding the UPF2 polypeptide, thereby reducing the FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in the neuronal or glial cell;
- wherein the UPF2 polypeptide comprises the amino acid sequence of SEQ ID NO:4.
Dependencies are inferred from the claim text.